Basilea Pharmaceutica - Another Cresemba milestone payment in the bank
The uptrend in Cresemba sales in Asia-Pacific and China triggered the receipt of Basilea’s third milestone payment of US$1.25m from Pfizer for the region (in addition to the March and May 2024 milestones). Asia-Pacific and specifically China have strategic importance as China comprises c 20% of the market opportunity for Cresemba. In-market sales for Cresemba remain robust globally and revenues have grown 24% y-o-y to US$489m during the 12 months ending March 2024. We expect Basilea to receive over CHF35m in milestones in H224 and for its overall activity to intensify in the next few weeks with the launch of the first Phase III fosmanogepix trial (in candidemia and invasive candidiasis) and the expected finalisation of a Zevtera US commercial partner, both significant inflection points.Basilea Pharmaceutica is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of bacterial infections, fungal infections, oncology and skin diseases. Co. focuses on antibiotics and antifungals as well as oncology and dermatology drugs. Co.'s portfolio spans from innovative early-stage through clinical late-stage drug candidates to a marketed product. In the context of its international commercialization organization, Co. has subsidiaries in Denmark, France, Germany, Italy, Spain and the United Kingdom.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.